Table 3.
Treatment of IED in patients with HS
| Treatment | Remission rate1 (%) |
|---|---|
| Topical steroid | 5/17 (29%) |
| Systemic steroid | 1/7 (14%) |
| Infliximab | 4/4 (100%) |
| Adalimumab2 | 2/4 (50%) |
| Methotrexate | 2/7 (29%) |
| Intraocular steroid injection | 0/1 |
1
number of cases achieving remission/total number of patients who used the specified medication
2
one of the two patients did not achieve remission with adalimumab and received only two doses because of rash and itching; the other patient used adalimumab intermittently for 3 years owing to financial issues